Sat, Aug 23, 2014, 3:44 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Spectrum Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • imho_dyodd imho_dyodd Dec 1, 2012 4:48 PM Flag

    Zevalin administration licensing requirements and it's impact to sales

    Zevalin (ibritumomab tiuxetan) is a murine anti-CD20 monoclonal antibody covalently bound the chelator tiuxetan which can securely chelate 90Y. We performed a randomized controlled trial comparing Zevalin radioimmunotherapy (RIT) with rituximab immunotherapy in 143 pts with relapsed or refractory low-grade, follicular, or CD20+ transformed B-cell NHL. The primary efficacy variable was ORR. The Zevalin regimen consists of Day 0 and D7 rituximab 250 mg/m[sup2] followed on Day 7 with 0.4 mCi/kg 90Y Zevalin. Control arm pts received 4 weekly doses of 375mg/m[sup2] rituximab. Baseline characteristics were well-balanced. There was no statistical difference between the Zevalin and rituximab groups in median age (60 vs. 57 yrs); histology (follicular 75% vs 83%); median prior therapy regimens (2); bone-marrow involvement (43% vs. 36%); splenomegaly (10% vs. 4%); bulky disease [greater than or equal to] 5 cm (45% vs. 44%), [greater than or equal to] 7 cm (21% vs. 26%), [greater than or equal to] 10 cm (8% vs. 7%); chemotherapy resistance (56% vs 64%); IPI risk group; performance status; or extranodal disease. All pts had acceptable biodistribution and dosimetry estimated radiation absorbed doses to normal organs. Zevalin adverse events were primarily hematologic. Six percent developed Gr 4 thrombocytopenia, 32% Gr 4 neutropenia, and 8% required hospitalization for infection. HAMA incidence was

 
SPPI
7.91+0.40(+5.33%)Aug 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Keurig Green Mountain, Inc.
NasdaqGSFri, Aug 22, 2014 4:00 PM EDT
Salesforce.com, Inc
NYSEFri, Aug 22, 2014 4:00 PM EDT